Status:

UNKNOWN

Effectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and BPD

Lead Sponsor:

Arkin

Collaborating Sponsors:

Sinai Centrum, Arkin, The Netherlands

Amsterdam UMC, location VUmc

Conditions:

Posttraumatic Stress Disorder (PTSD)

Borderline Personality Disorder (BPD)

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The goal of PROSPER-B is to study effectiveness of EMDR compared to integrated DBT-EMDR in treatment-seeking, adult patients with comorbid PTSD and Borderline Personality Disorder (BPD).

Detailed Description

Posttraumatic stress disorder (PTSD) is highly comorbid with personality disorders (PD), mainly borderline (BPD) and cluster C personality disorders (CPD). It is not clear yet what treatment is most e...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Diagnosed with PTSD (309.81), and
  • Diagnosed with a borderline personality disorder (301.83) or at least 4 BPD symptoms
  • To be eligible for the study, both patients and healthy controls (for the MRI scans) have to:
  • Be aged between 18 and 65 years
  • Give written informed consent
  • Speak / understand Dutch sufficiently
  • Exclusion criteria:
  • Current psychosis
  • Comorbidity interfering with treatment or randomisation (severe outward aggression, antisocial PD, treatment interfering addiction or eating disorders, somatic problems)
  • Primary diagnosis of paranoid, schizoid, schizotypal, narcissistic, histrionic or antisocial PD
  • Mental retardation
  • Additional exclusion criteria for the MRI substudy are:
  • Pregnancy
  • Metal implants (such as pacemakers, etc.);
  • Somatic disorders interfering with brain functioning
  • Claustrophobia
  • High dose use of benzodiazepines
  • For the healthy controls, current psychiatric diagnosis is an additional exclusion criterion.

Exclusion

    Key Trial Info

    Start Date :

    June 1 2018

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    April 2 2023

    Estimated Enrollment :

    126 Patients enrolled

    Trial Details

    Trial ID

    NCT03833453

    Start Date

    June 1 2018

    End Date

    April 2 2023

    Last Update

    September 23 2020

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Sinai Centrum

    Amstelveen, Noord-Holand, Netherlands, 1180EB